Novartis Pharmaceutical Corporation
150 Industrial Road
About Novartis Pharmaceutical CorporationNovartis is a world leader in the research and development of products that protect and improve health and well-being. Our global mission is to discover, develop and successfully market innovative products to ease suffering and enhance the quality of life of our patients.
Novartis has been recognized for its admirable reputation, commitment to ethics, status as a respected pillar of the industry and for being an outstanding workplace for its employees. In recent years, we’ve been named among the “Most Admired” (FORTUNE & MedAdNews), “Most Innovative” (Fast Company), and “Most Ethical” (PharmaVoice) companies in the world. With global headquarters in Basel, Switzerland, and U.S. headquarters in East Hanover, New Jersey, the Novartis Group companies employ about 100,000 people and have a presence in more than 140 countries.
Our campus in San Carlos, just south of San Francisco, is part of Novartis Pharmaceuticals Corp. It is unique because it is home to both a Technical Research and Development site and a Pharmaceutical Operations commercial manufacturing site which combined employ 250+ people.
Our TRD site is focused on developing respiratory products for diseases such as cystic fibrosis, asthma and COPD. It incorporates drug development, process development, clinical manufacturing, inhalation device development, and proprietary equipment design. The site’s primary focus is particle engineering in which the facility pioneered the use of spray-drying technology.
Our Pharmaceutical Operations commercial manufacturing site produces an inhaled form of dry powder tobramycin for the TOBI Podhaler, which is used in the prevention of chronic lung infections in cystic fibrosis patients. It is approved for use in the United States, Canada, Europe and Saudi Arabia. The TOBI Podhaler not only gives patients a portable option for treatment, but also dramatically reduces their treatment time so they can live more independent lives.
San Carlos is a significant contributor to Novartis' growth in respiratory medicines, as well as continuing to actively support surrounding communities. We are constantly looking for the best and the brightest to join our talented team of scientists, engineers, operators, quality assurance and control, product development and support services. About one-quarter of the employees in San Carlos hold advanced science degrees. We offer a work environment that values innovation and the continuous pursuit of knowledge in order to provide the best products to our patients. Novartis offers a variety of competitive and comprehensive benefits for eligible full time employees.
To learn more about employment opportunities at the San Carlos Novartis site, visit www.novartis and click on "Careers." From there, go to "Job Search" and type "San Carlos" in the search bar.
37 articles with Novartis Pharmaceutical Corporation
Novartis Initiates Study Evaluating Impact of Higher Dosing of Cosentyx in Patients With Ankylosing Spondylitis
The primary endpoint of ASLeap is to determine the difference between Cosentyx 300 mg and Cosentyx 150 mg at Week 52 based on the proportion of subjects achieving inactive disease status based on the ASDAS.
Important New Analysis Shows That Novartis Pharmaceutical Corporation' Entresto Is Associated With Higher Relative Health-Related Quality Of Life Scores Among HFrEF Patients
Timely Use Of Novartis Pharmaceutical Corporation' Entresto Could Prevent Or Postpone Over 28,000 US Deaths Per Year Among Hfref Patients, According To An Expert Analysis In JAMA Cardiology
Novartis Pharmaceutical Corporation To Present Pivotal Data In Hematologic And Solid Tumor Cancers At 2016 ASCO Annual Meeting
Novartis Pharmaceutical Corporation Highlights Clinical Advances At American Society of Hematology 2015, Underscoring Leadership In Hematology Research
Patients With Aggressive Form Of Melanoma Lived For More Than Two Years On Average When Taking Novartis Pharmaceutical Corporation Therapies Tafinlar + Mekinist
Novartis Pharmaceutical Corporation Announces FDA Approval For Jadenu To Simplify Treatment Administration For Patients With Chronic Iron Overload
Novartis Pharmaceutical Corporation AIN457 (secukinumab) Showed Significant Symptom Improvement In Two Pivotal Phase 3 ankylosing spondylitis Studies
Novartis Pharmaceutical Corporation To Present First IL-17A Phase 3 Data For AIN457 (secukinumab) In Psoriatic Arthritis And Ankylosing Spondylitis At ACR 2014
Novartis Pharmaceutical Corporation Release: U.S. Results From First Global Survey Of Neuroendocrine Tumor (NET) Patients Reveal Profound Impact Of This Rare Cancer On Quality Of Life
Novartis Pharmaceutical Corporation Teams Up With Multiple Sclerosis Advocate And Musician David Osmond To Launch MS Education Initiative Our Voice In Song™
SCRS Announces Novartis Pharmaceutical Corporation and Quintiles, Inc. as Winners of the 2013 Eagle Awards